

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AdvanCell Pty Ltd.
Petitioner

v.

Sciencons AS and ARTBIO, Inc.
Patent Owner

Post Grant Review No.: PGR2025-00029

PETITIONER'S MOTION TO SEAL

INDEX OF EXHIBITS

Exhibit No.	Description
1001	U.S. Patent Number 12,125,603.
1002	Declaration of Saed Mirzadeh.
1003	Hassfjell, Sindre P. and Hoff, Per, “A Generator for Production of ^{212}Pb and ^{212}Bi ”, Appl. Radiat. Isot., vol. 45, no. 10, pp 6-25 (1994) (“ Hassfjell-Hoff ”).
1004	WorldCat Index for Hassfjell-Hoff .
1005	International Publication Number WO 01/60417.
1006	File History of U.S. Patent No. 12,125,603.
1007	US Patent Application Publication No. 2018/0047474 A1 (“ O’Hara ”).
1008	Hassan, Ahmed and Alnaser, Ibrahim Abdullah, “A Review of Different Manufacturing Methods of Metallic Foams” ACS Omega 2024 9 (6), 6280-6295 DOI: 10.1021/acsomega.3c08613 (“ Hassan ”).
1009	Lefebvre, Louis-Philippe, Banhart, John, and Dunand, David C., “Porous Metals and Metallic Foams: Current Status and Recent Developments,” Advanced Engineering Materials, 10, September 9, pp. 775-787, 2008 https://doi.org/10.1002/adem.200800241 , (“ Lefebvre ”).
1010	U.S. Patent Number 3,087,807.
1011	“Radioisotopes,” International Atomic Energy Agency, https://www.iaea.org/topics/nuclear-science/isotopes/radioisotopes (last accessed February 11, 2025).
1012	File History of U.S. Patent Application Serial No. 18/680,605.
1013	File History of U.S. Patent Application Serial No. 18/680,372.
1014	Hassfjell, Sindre, “A ^{212}Pb generator based on a ^{228}Th source”, Appl. Radiat. Isot., vol. 55, no. 4, pp 433-439 (2001) (“ Hassfjell-2001 ”).
1015	U.S. Patent Number 6,592,843.
1016	“O-Ring Handbook,” Parker Hannifin Corporation, https://www.hdslippers.com/cgi-bin/pdf/Catalogues/05-O-Ring-Handbook_ODE5705-EN%20Luglio%202015.pdf (last accessed March 7, 2025).
1017	Declaration of Per Hoff.
1018	Excerpts of Merriam-Webster’s Collegiate Dictionary, 11 th ed. (2018).

Exhibit No.	Description
1019	Declaration of Jennifer Librach Nall
1020	U.S. Patent Number 12,394,533.
1021	Conroy Exhibit 3: Fierce Pharma, “Nucleus RadioPharma links up with ARTBIO to help produce prostate cancer candidate for clinical trials” (May 7, 2024).
1022	Conroy Exhibit 4: ARTBIO, “ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials.”
1023	Conroy Deposition Transcript.
1024	Nat’l Libr. of Med., <i>Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (ARTISAN)</i> (last updated Apr. 7, 2026), https://clinicaltrials.gov/study/NCT07214961 (describing active clinical trials of AB001 by ARTBIO).
1025	https://artbio.com/ARTBIO-Announces-dosing-of-Two-Cohorts-with-AB001 (describing these trials as way to “develop[] a new class of 212Pb alpha radioligand therapies”).
1026	ARTBIO, “ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials” (May 7, 2024), https://artbio.com/artbio-nucleus-radiopharma-collaboration-manufacture-gmp-grade-therapeutic-products-radioisotope-pb-212-support-emerging-clinical-trials .
1027	U.S. Patent No. 12,406,776

In accordance with 37 C.F.R. § 42.14, Petitioner moves to seal EX1023 (the deposition transcript of Charles Conroy, dated April 2, 2026) and Petitioner's Reply to Patent Owner's Response (Paper 21), filed herewith, in accordance with the pending Joint Motion for Entry of the Default Protective Order. See Paper 20.

Certain portions of the deposition transcript (EX1023) were designated confidential by Patent Owner and its expert Mr. Conroy during the deposition of Mr. Conroy. Exhibit 1023 should not be public because it contains confidential information about Mr. Conroy's financial interest in a third party. Members of the public may refer to the redacted copy of Exhibit 1023. Certain portions of Petitioner's Reply to Patent Owner's Response that references Exhibit 1023 is confidential for the same reasons. Members of the public may refer to the redacted copy of Petitioner's Reply to Patent Owner's Response.

Date: April 29, 2026

Respectfully submitted,

/s/ Jennifer Librach Nall

Jennifer Librach Nall

Reg. No. 57,053

DLA Piper LLP US

303 Colorado Street, Suite 3000

Austin, TX 78701

Phone: + 1 512 457 7249

Fax: + 1 512 721 2249

jennifer.nall.ptab@us.dlapiper.com

Attorney for Petitioner, AdvanCell
Isotopes Pty Ltd

CERTIFICATE OF SERVICE

The undersigned certifies that on April 29, 2026, a true and correct copy of the forgoing document was served by emailing a copy of same (by agreement) to the following attorneys for the Patent Owner:

Michael T. Rosato (mrosato@wsgr.com)

Patrick M. Medley (pmedley@wsgr.com)

Michael J. Hostetler (mhostetler@wsgr.com)

Respectfully submitted,

/s/ Jennifer Librach Nall

Jennifer Librach Nall